Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.830
+0.030 (1.67%)
At close: Jun 26, 2026, 4:00 PM EDT
1.825
-0.005 (-0.28%)
After-hours: Jun 26, 2026, 6:29 PM EDT
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aldeyra Therapeutics stock have an average target of 5.50, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 200.55% from the current stock price of 1.83.
Analyst Consensus: Buy
* Price targets were last updated on May 11, 2026.
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $2 | Hold | Reiterates | $2 | +9.29% | May 11, 2026 |
| BTIG | BTIG | Buy Maintains $9 | Buy | Maintains | $9 | +391.80% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
1.67M
Revenue Next Year
19.75M
from 1.67M
Increased by 1,084.95%
EPS This Year
-0.33
from -0.56
EPS Next Year
-0.18
from -0.33
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.0M | 45.4M | |
| Avg | 1.7M | 19.7M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 2,624.0% | 445.8% |
| Avg | 1,085.0% | 279.3% |
| Low | -100.0% | 112.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.33 | -0.18 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.